Synchrotron microbeam radiation therapy (MRT), a spatially fractionated preclinical radiotherapy, is more efficient than broad beam irradiation (BB) at opening the blood-brain tumor barrier of intracranial rodent glioblastomas. MRT-induced increase of tumor vascular permeability is significantly greater, earlier and more prolonged than in the BB alone group, especially in highly proliferative areas. MRT targeted all tumor regions, including areas not impacted by BB. High dose microbeams might be used to facilitate the delivery of intravenously injected drugs to tumoral tissue: Adjuvant chemotherapy might thus be more effective when coupled with MRT than with homogeneous radiation fields used in conventional radiotherapy.
This abstract and the presentation materials are available to members only; a login is required.